# The Digitalisation of Healthcare

Dr. Anushka Patchava Deputy Chief Medical Officer, Vitality UN and WEF Expert Advisor

AMII SUMMIT, November 2022

### **COVID19:** a catalyst for digital health

Pre-COVID, digital health was a differentiator, now it's an expectation and it's here to stay







# Global Semiconductor Shortage Need for Prioritisation of Healthcare Capabilities

# Semiconductors shortage: why the medtech sector must be prioritised


# Global semiconductor shortage 'a risk to patient health' Patient health could be

OUT-LAW NEWS | 05 Jan 2022 | 12:10 pm | 3 min. read

 $(\boxtimes)$ 

Patient health could be at risk if the global shortage of semiconductors affects the ability of health care providers to fit or issue functioning medical devices or medical technologies, an expert in digital health has warned.

### Exponential change will accelerate the pace of disruption





### What are the key factors making the sector attractive?

Global digital health funding has experienced **34% CAGR 2017-2021**<sup>4</sup> **with mega deals rising over 2.6x** over the Q1 2020 levels and **5x** over Q2 2020 levels<sup>3</sup>





In 2021 global digital health venture funding amassed to \$21.8B in 2021<sup>1</sup>, up 2.6x compared to 2019. with \$4.66B +2.99x YoY deployed across Europe, across 249 deals +0x YoY<sup>2</sup>demonstrating rising attractiveness and potential of this sector.

\$14.68B




■ Middle East ■ Europe ■ APAC ■ North America

1. Health Trends Insight Report, Galen 2021

- 2. Pitchbook
- 3. Global Digital Health Report, Deloitte, 2021
- CB Insights Report, 2021

26% of global digital health ventures are headquartered in Europe, with a predominance of early stage and Series A ventures dominating the space right now.
Only 10% of ventures incorporated have exited via acquisition, IPO or SPAC<sup>2.3</sup>




■ Early Stage ■ Series A ■ Series B ■ Series C ■ Series D & Beyond ■ Exits




### The UK remains at the core of innovation and funding activity...

The Top 4 countries by funding value are UK, France, Sweden and Germany; with research and telemedicine being the key areas of interest capturing over 40% of the capital deployed.




■ Early Stage ■ Series A ■ Series B ■ Series C ■ Series D & Beyond

0	Digital Health Cluster	Total Funding in Europe (2021)	Rank in 2020	Largest Deal in 2021
	Research	\$1.16B	#2	Exscientia \$300.0M (Series D1)
ta S	Telemedicine	\$700.1M	#1	Kry (also LIVI \$316.5M (Series D)
	Patient Solutions	\$565.5M	#4	\$130.0M (Series C
	Wellness	\$532.8M	#3	OURA \$100.0M (Series C
Ş9;	InsurTech	\$446.8M	#5	Alar \$261.7M (Series D



### Where has the investment been in digital health tech?

There has been an explosion in venture funding for digital health disrupters




■ Middle East ■ Europe ■ APAC ■ North America

50% of funding in four key areas: health management solutions, patient solutions, telemedicine and wellness

# Year on year growth in global digital health venture funding

### Volume Share of Global Digital Health Ventures by Cluster<sup>1</sup>



Health Management Solutions

- Patient Solutions
- Wellness
- Medical Diagnostics
- Remote Monitoring
- Telemedicine
- Health Services Search
- Research
- Online Marketplace
- Medical Education
- Other Clusters



### Unsurprisingly, teleconsultations have now taken off...

kry		(+) D(	• DOKTOR.SE		i e S	
Kry (a	also LIVI)	D	oktor.se			ieso
COUNTRY	PRIMARY CATEGORY	COUNTRY	PRIMARY CATEGORY	c	OUNTRY	Р
Sweden	Teleconsultation	Sweden	Teleconsultation	U	Inited Kingdom	т
LATEST FUNDING	VALUATION	LATEST FUNDING	VALUATION	L.	ATEST FUNDING	v
\$316.5M (Series D)	\$2.44B	\$61.3M (Series D)	\$500.7M		53.0M Series B)	
INC. DATE	MATURITY SCORE	INC. DATE	MATURITY SCORE	IN	NC. DATE	M
12 / 2017	82.8	4 / 2016	82.8		9 / 20	00

#### DESCRIPTION

(known as LIVI in the UK, Germany and France) Kry delivers video GP consultations within minutes to patients via their mobile devices. LIVI provides equitable access to high-quality health care - at the patient's own convenience.

#### DESCRIPTION

Doktor.se is a Swedish e-health company that helps members find, book and get access to the best healthcare. Doktor.se provides its services through video app meetings and phone calls. Using their own doctors and nurses, Doktor.se gives employees at member companies access to fast and accurate health care, with referrals to physical exams, tests and specialized care.

i 🖰 S 🔎		
ie	eso	
COUNTRY	PRIMARY CATEGORY	
United Kingdom	Teleconsultation	
LATEST FUNDING	VALUATION	
\$53.0M (Series B)	\$254.4M	
INC. DATE	MATURITY SCORE	
9 / 2000	75.7	

#### DESCRIPTION

ieso is a world leading digital health company specialising in internet-enabled, evidence-based psychological therapies. Their modality of providing online therapy through written conversation and strict adherence to disorderspecific treatment protocols ensures that patients experience the best possible evidencebased cognitive behavioural therapy (CBT) for their needs.



### And of course, there remains a focus on Cancer

Oncology has seen an 8.5x increase in funding; patient support tools and early detection and targeted therapies

### How specific do we want to be?

#### **POPULATION-BASED**

- Non-specific products, personalised outputs
- Patient-level disease tracking & monitoring

Cardiogram, Physiological sensor and deep learning to predict cardiovascular risk

#### SPECIALTY / SUBSPECIALTY

- Customisation of treatment based on patient factors
- Curated dosage, form, packaging and delivery
- Tumor or genetic sequencing to select treatment protocols
- Therapies targeted to genetic subpopulations

Patient-specific pharmaceutical compounding for dose adjustment, BRAF V600E mutant identification determining cancer treatment

#### **RARE & ORPHAN**

- Small patient populations, mainly genetic disease
- Patient-genomics driven diagnosis and treatment

Migalastat, Amicus Therapeutics' Precision Medicine for Fabry Disease

#### 1:1 SINGLE PATIENT

- Uses the biology of an individual patient
- Patient products become the patient's therapy

LSTONE	<u>Q</u>	tios
ne Medical	Artic	os Pharma
PRIMARY CATEGORY	COUNTRY	PRIMA
Diagnosis Tools	United Kingdom	Geno Resea
VALUATION	LATEST FUNDING	VALUA
\$446.2M	\$153.0M (Series C)	
MATURITY SCORE	INC. DATE	MATU
74.1	12 / 2015	
	ne Medical PRIMARY CATEGORY Diagnosis Tools VALUATION \$446.2M MATURITY SCORE	ne Medical     Artic       PRIMARY CATEGORY     COUNTRY       Diagnosis Tools     United Kingdom       VALUATION     LATEST FUNDING       \$446.2M     \$153.0M       (Series C)     INC. DATE

**Example Ventures** 

#### DESCRIPTION

Owlstone has developed the Breath Biopsy platform, using breath analysis for precision medicine and the early detection of disease.

Artios	Pharma
	PRIMARY CATEGORY
dom	Genomics Related Research
ING	VALUATION
	\$900.0M
	MATURITY SCORE

75.4

#### DESCRIPTION

Artios is a leading independent DNA Damage Response (DDR) company focused on developing first-in-class treatments for cancer. Artios began clinical trials in February 2021 of its small-molecule ATR inhibitor, ART0380, in patients with advanced or metastatic solid tumours.

Most

Least

Patient specificity



But as we go through 2022, we are beginning to see signs of a downturn..

# \$10.4B

# Global digital health funding in Q1'22.

Global digital health funding reached \$10.4B in Q1'22, a 36% decrease compared to Q4'21 and a 6-quarter low.

Digital health startups saw a larger funding drop-off in Q1'22 than the fintech and retail tech sectors, which only saw 18% and 11% funding decreases QoQ, respectively. 1

# -52%

### Decrease in megaround funding.

Mega-round funding more than halved in Q1'22, as investors backed fewer \$100M+ deals to digital health startups QoQ.

At \$4.4B, total mega-round funding represented just 42% of all digital health dollars invested in Q1'22, down from 57% in Q4'21 helping to explain the 36% drop in overall funding.<sup>1</sup>

### **138** M&A deals in Q1'22.

M&A activity in the digital health sector has held above 100 deals for 7 consecutive quarters. Consolidation took off in 2021 and remained elevated in Q1'22, with 138 deals.

As dominant players emerge in this fragmented market, we expect to see this consolidation trend continue. 1

# **-96**%

### Drop in IPOs.

IPO activity ground to a halt in Q1'22, with just 1 IPO compared to 23 in the previous quarter.

Further, no SPAC deals occurred in Q1'22, down from the 6 recorded in Q4'21.

This drop in public exits is likely due to disappointing IPO returns in 2021, among other factors.<sup>1</sup>



One of the most talked about IPO's Bablyon (NYSE)is down 81.25% YTD despite a MKTCAP of 487.15M and over 200M p.a ARR. Analysts had previously downgraded it to 'sell' but last week upgraded this to 'hold', despite missing EPS predictions<sup>2</sup>

CB Insights
 Rock Health data





## What is also important to note is high demand areas have seen funding fall..

With market consolidation occurring mainly through sales partnerships or vertical integration, we are likely to see the robust, scaleable solutions succeed, and leading incumbents may face more pressure from consolidation among smaller players increasing competition and improving market efficiency. An example of this is Teladoc and Livongo in the United States.

This type of activity is likely to benefit Vitality and the consumer in the long-term, bringing together capabilities (health care professionals, digital tools, data science) into one ecosystem for better health.

Some would argue innovation and personalised solutions (targeting niche or specialised needs) are likely to be stifled. A critical factor for all Vitality partnerships remains in conducting detailed due diligence including financial position with all start-ups we partner with.






### Q1'22 telehealth funding falls off 32% to reach \$3.2B

1. CB Insights

## Five healthcare trends to watch out for

Digital health is revolutionalising the way we think about healthcare



## Innovation in digital healthcare is broad ranging, and exciting

There are many players and examples of use cases which have promising outcomes

### Telemedicine

LIVI & tytocare

See a doctor from the palm of your

hand and comfort at home.

Primary Care and beyond; with

diagnostic support.

### **Digital health**

onko

Focus, track or augmenting what can be provided, augmenting services in traditional clinics and supporting clinical systems.

### **Digital therapeutics**



Evidence-based interventions, delivered digitally via software to treat, manage or prevent a disorder or health condition.

### IoT

# alexa

Benefits of voice for health; medicines ordering, information sharing, connectivity whilst in care, and insurance claims.

# VR/AR

# PROXIMIE

Creating 'other reality' environments leading to faster and more effective collaboration and diagnostics.

## Remote monitoring


# 🕀 H U M A

Remote patient monitoring for example managing 'non critical' patients at home, through connected devices and services.

### **Benefits for the system**



Digital health is set to improve clinical, effectiveness, efficiency and patient outcomes



- More options for early diagnosis, prevention and management of all conditions
- Improved capacity, in a strained system
- **Proactive, not reactive**, healthcare
- **Personalised** at its core
- Better value
- **Sustainability**, the ESG agenda
- Reduction in health inequalities?

# Thank You

Anushka.Patchava@vitality.co.uk

- AA